• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PIAS1 调节纹状体转录、DNA 损伤修复和 SUMO 化,与亨廷顿病有关。

PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington's disease.

机构信息

Department of Neurobiology and Behavior, University of California, Irvine, CA 92697.

Department of Psychiatry and Human Behavior, University of California, Irvine, CA 92697.

出版信息

Proc Natl Acad Sci U S A. 2021 Jan 26;118(4). doi: 10.1073/pnas.2021836118.

DOI:10.1073/pnas.2021836118
PMID:33468657
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7848703/
Abstract

DNA damage repair genes are modifiers of disease onset in Huntington's disease (HD), but how this process intersects with associated disease pathways remains unclear. Here we evaluated the mechanistic contributions of protein inhibitor of activated STAT-1 (PIAS1) in HD mice and HD patient-derived induced pluripotent stem cells (iPSCs) and find a link between PIAS1 and DNA damage repair pathways. We show that PIAS1 is a component of the transcription-coupled repair complex, that includes the DNA damage end processing enzyme polynucleotide kinase-phosphatase (PNKP), and that PIAS1 is a SUMO E3 ligase for PNKP. Pias1 knockdown (KD) in HD mice had a normalizing effect on HD transcriptional dysregulation associated with synaptic function and disease-associated transcriptional coexpression modules enriched for DNA damage repair mechanisms as did reduction of PIAS1 in HD iPSC-derived neurons. KD also restored mutant HTT-perturbed enzymatic activity of PNKP and modulated genomic integrity of several transcriptionally normalized genes. The findings here now link SUMO modifying machinery to DNA damage repair responses and transcriptional modulation in neurodegenerative disease.

摘要

DNA 损伤修复基因是亨廷顿病 (HD) 发病的修饰因子,但这一过程如何与相关疾病途径交叉仍不清楚。在这里,我们评估了蛋白抑制剂 of activated STAT-1 (PIAS1) 在 HD 小鼠和 HD 患者来源的诱导多能干细胞 (iPSC) 中的作用机制,并发现了 PIAS1 与 DNA 损伤修复途径之间的联系。我们表明,PIAS1 是转录偶联修复复合物的一个组成部分,该复合物包括 DNA 损伤末端加工酶多核苷酸激酶磷酸酶 (PNKP),并且 PIAS1 是 PNKP 的 SUMO E3 连接酶。在 HD 小鼠中敲低 PIAS1 (KD) 对与突触功能相关的 HD 转录失调具有正常化作用,与 DNA 损伤修复机制相关的疾病相关转录共表达模块也具有正常化作用,而在 HD iPSC 衍生神经元中降低 PIAS1 也具有正常化作用。KD 还恢复了突变 HTT 扰乱的 PNKP 酶活性,并调节了几个转录正常化基因的基因组完整性。这里的发现现在将 SUMO 修饰机制与神经退行性疾病中的 DNA 损伤修复反应和转录调节联系起来。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8768/7848703/d23592bfd916/pnas.2021836118fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8768/7848703/b87a5ae00bee/pnas.2021836118fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8768/7848703/ee607b9dae44/pnas.2021836118fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8768/7848703/437ee8a6a9ed/pnas.2021836118fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8768/7848703/8c89c5b2d42c/pnas.2021836118fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8768/7848703/d23592bfd916/pnas.2021836118fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8768/7848703/b87a5ae00bee/pnas.2021836118fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8768/7848703/ee607b9dae44/pnas.2021836118fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8768/7848703/437ee8a6a9ed/pnas.2021836118fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8768/7848703/8c89c5b2d42c/pnas.2021836118fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8768/7848703/d23592bfd916/pnas.2021836118fig05.jpg

相似文献

1
PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington's disease.PIAS1 调节纹状体转录、DNA 损伤修复和 SUMO 化,与亨廷顿病有关。
Proc Natl Acad Sci U S A. 2021 Jan 26;118(4). doi: 10.1073/pnas.2021836118.
2
A PIAS1 Protective Variant S510G Delays polyQ Disease Onset by Modifying Protein Homeostasis.PIAS1 保护变体 S510G 通过改变蛋白质平衡来延迟 polyQ 疾病的发作。
Mov Disord. 2022 Apr;37(4):767-777. doi: 10.1002/mds.28896. Epub 2021 Dec 23.
3
PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo.PIAS1在体内调节突变型亨廷顿蛋白的积累及与亨廷顿舞蹈病相关的表型。
Neuron. 2016 May 4;90(3):507-20. doi: 10.1016/j.neuron.2016.03.016. Epub 2016 Apr 14.
4
Mutant huntingtin impairs PNKP and ATXN3, disrupting DNA repair and transcription.突变亨廷顿蛋白损害 PNKP 和 ATXN3,破坏 DNA 修复和转录。
Elife. 2019 Apr 17;8:e42988. doi: 10.7554/eLife.42988.
5
SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation.SUMO-2 和 PIAS1 调节不溶性突变 huntingtin 蛋白的积累。
Cell Rep. 2013 Jul 25;4(2):362-75. doi: 10.1016/j.celrep.2013.06.034. Epub 2013 Jul 18.
6
Fructose-2,6-bisphosphate restores DNA repair activity of PNKP and ameliorates neurodegenerative symptoms in Huntington's disease.果糖-2,6-二磷酸恢复 PNKP 的 DNA 修复活性,并改善亨廷顿病的神经退行性症状。
Proc Natl Acad Sci U S A. 2024 Sep 24;121(39):e2406308121. doi: 10.1073/pnas.2406308121. Epub 2024 Sep 19.
7
Phosphorylation of protein inhibitor of activated STAT1 (PIAS1) by MAPK-activated protein kinase-2 inhibits endothelial inflammation via increasing both PIAS1 transrepression and SUMO E3 ligase activity.丝氨酸/苏氨酸蛋白激酶激活的蛋白激酶 2 磷酸化信号转导和转录激活因子 1 抑制蛋白(PIAS1)可通过增加 PIAS1 转录抑制和 SUMO E3 连接酶活性抑制内皮炎症。
Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):321-9. doi: 10.1161/ATVBAHA.112.300619. Epub 2012 Nov 29.
8
Protein inhibitor of activated STAT 1 (PIAS1) is identified as the SUMO E3 ligase of CCAAT/enhancer-binding protein β (C/EBPβ) during adipogenesis.在脂肪生成过程中,被激活的 STAT1 的蛋白抑制剂(PIAS1)被鉴定为 CCAAT/增强子结合蛋白β(C/EBPβ)的 SUMO E3 连接酶。
Mol Cell Biol. 2013 Nov;33(22):4606-17. doi: 10.1128/MCB.00723-13. Epub 2013 Sep 23.
9
The transcriptional activity of co-activator AIB1 is regulated by the SUMO E3 ligase PIAS1.共激活因子 AIB1 的转录活性受 SUMO E3 连接酶 PIAS1 的调节。
Biol Cell. 2012 May;104(5):287-96. doi: 10.1111/boc.201100116. Epub 2012 Mar 7.
10
Linking nuclear matrix-localized PIAS1 to chromatin SUMOylation via direct binding of histones H3 and H2A.Z.通过组蛋白 H3 和 H2A.Z 与核基质定位的 PIAS1 的直接结合将 SUMO 化与染色质联系起来。
J Biol Chem. 2021 Oct;297(4):101200. doi: 10.1016/j.jbc.2021.101200. Epub 2021 Sep 17.

引用本文的文献

1
Huntingtin preserves mitochondrial genome integrity in neurons, which is impaired in Huntington's disease.亨廷顿蛋白可维持神经元中线粒体基因组的完整性,而在亨廷顿舞蹈症中这种完整性会受到损害。
bioRxiv. 2025 Jul 24:2025.07.24.666629. doi: 10.1101/2025.07.24.666629.
2
Optimized AAV capsids for basal ganglia diseases show robust potency and distribution.用于治疗基底神经节疾病的优化腺相关病毒衣壳显示出强大的效力和分布。
Nat Commun. 2025 May 19;16(1):4653. doi: 10.1038/s41467-025-60000-3.
3
SPOP mutations increase PARP inhibitor sensitivity via CK2/PIAS1/SPOP axis in prostate cancer.

本文引用的文献

1
Aberrant Development Corrected in Adult-Onset Huntington's Disease iPSC-Derived Neuronal Cultures via WNT Signaling Modulation.通过 WNT 信号转导调控,纠正成年发病亨廷顿病 iPSC 衍生神经元培养中的异常发育。
Stem Cell Reports. 2020 Mar 10;14(3):406-419. doi: 10.1016/j.stemcr.2020.01.015. Epub 2020 Feb 27.
2
Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.用 BET 溴结构域抑制剂 JQ1 进行治疗,对 R6/2 亨廷顿病小鼠具有选择性的有害作用。
Hum Mol Genet. 2020 Jan 15;29(2):202-215. doi: 10.1093/hmg/ddz264.
3
SUMOylation in Neurodegenerative Diseases.
SPOP突变通过CK2/PIAS1/SPOP轴增加前列腺癌对PARP抑制剂的敏感性。
JCI Insight. 2025 Apr 22;10(8). doi: 10.1172/jci.insight.186871.
4
Accelerated epigenetic aging in Huntington's disease involves polycomb repressive complex 1.亨廷顿病中加速的表观遗传衰老涉及多梳抑制复合体1。
Nat Commun. 2025 Feb 11;16(1):1550. doi: 10.1038/s41467-025-56722-z.
5
Enhancing Transcriptomic Insights into Neurological Disorders Through the Comparative Analysis of Shapley Values.通过夏普利值的比较分析增强对神经系统疾病的转录组学洞察
Curr Issues Mol Biol. 2024 Nov 29;46(12):13583-13606. doi: 10.3390/cimb46120812.
6
Therapeutic approaches targeting aging and cellular senescence in Huntington's disease.针对亨廷顿病的衰老和细胞衰老的治疗方法。
CNS Neurosci Ther. 2024 Oct;30(10):e70053. doi: 10.1111/cns.70053.
7
Dysregulation of protein SUMOylation networks in Huntington's disease R6/2 mouse striatum.亨廷顿舞蹈病R6/2小鼠纹状体中蛋白质类泛素化修饰网络的失调
Brain. 2025 Apr 3;148(4):1212-1227. doi: 10.1093/brain/awae319.
8
Hydrogen Sulfide: A Versatile Molecule and Therapeutic Target in Health and Diseases.硫化氢:健康与疾病中的多功能分子和治疗靶点。
Biomolecules. 2024 Sep 10;14(9):1145. doi: 10.3390/biom14091145.
9
Poly ADP-ribose signaling is dysregulated in Huntington disease.多聚 ADP - 核糖信号传导在亨廷顿病中失调。
Proc Natl Acad Sci U S A. 2024 Oct;121(40):e2318098121. doi: 10.1073/pnas.2318098121. Epub 2024 Sep 27.
10
SUMO and the DNA damage response.小泛素样修饰蛋白与DNA损伤反应
Biochem Soc Trans. 2024 Apr 24;52(2):773-792. doi: 10.1042/BST20230862.
神经退行性疾病中的小泛素样修饰蛋白化作用
Gerontology. 2020;66(2):122-130. doi: 10.1159/000502142. Epub 2019 Sep 10.
4
Roles of Ubiquitination and SUMOylation in DNA Damage Response.泛素化和 SUMO 化在 DNA 损伤反应中的作用。
Curr Issues Mol Biol. 2020;35:59-84. doi: 10.21775/cimb.035.059. Epub 2019 Aug 18.
5
DNA Damage Repair in Huntington's Disease and Other Neurodegenerative Diseases.亨廷顿病和其他神经退行性疾病中的 DNA 损伤修复。
Neurotherapeutics. 2019 Oct;16(4):948-956. doi: 10.1007/s13311-019-00768-7.
6
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease.用于亨廷顿病治疗的突变 HTT 的等位基因选择性转录抑制。
Nat Med. 2019 Jul;25(7):1131-1142. doi: 10.1038/s41591-019-0478-3. Epub 2019 Jul 1.
7
MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1.MSH3改变亨廷顿舞蹈症和1型强直性肌营养不良症中的体细胞不稳定性和疾病严重程度。
Brain. 2019 Jun 19;142(7):1876-86. doi: 10.1093/brain/awz115.
8
Mutant huntingtin impairs PNKP and ATXN3, disrupting DNA repair and transcription.突变亨廷顿蛋白损害 PNKP 和 ATXN3,破坏 DNA 修复和转录。
Elife. 2019 Apr 17;8:e42988. doi: 10.7554/eLife.42988.
9
AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models.腺相关病毒5型微小亨廷顿蛋白基因疗法在亨廷顿舞蹈病小鼠模型中显示出持续降低亨廷顿蛋白水平并改善功能。
Mol Ther Methods Clin Dev. 2019 Mar 16;13:334-343. doi: 10.1016/j.omtm.2019.03.002. eCollection 2019 Jun 14.
10
Altered Synaptic Vesicle Release and Ca Influx at Single Presynaptic Terminals of Cortical Neurons in a Knock-in Mouse Model of Huntington's Disease.亨廷顿舞蹈病基因敲入小鼠模型中皮质神经元单个突触前终末处的突触小泡释放及钙内流改变
Front Mol Neurosci. 2018 Dec 24;11:478. doi: 10.3389/fnmol.2018.00478. eCollection 2018.